DE60305026D1 - 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten - Google Patents

3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Info

Publication number
DE60305026D1
DE60305026D1 DE60305026T DE60305026T DE60305026D1 DE 60305026 D1 DE60305026 D1 DE 60305026D1 DE 60305026 T DE60305026 T DE 60305026T DE 60305026 T DE60305026 T DE 60305026T DE 60305026 D1 DE60305026 D1 DE 60305026D1
Authority
DE
Germany
Prior art keywords
dihydrochinolin
compounds
receptor antagonists
nr2b receptor
nr2b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60305026T
Other languages
English (en)
Other versions
DE60305026T2 (de
Inventor
M Kawamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60305026D1 publication Critical patent/DE60305026D1/de
Application granted granted Critical
Publication of DE60305026T2 publication Critical patent/DE60305026T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60305026T 2002-04-26 2003-04-15 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten Expired - Fee Related DE60305026T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26
US375939P 2002-04-26
PCT/IB2003/001556 WO2003091241A1 (en) 2002-04-26 2003-04-15 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists

Publications (2)

Publication Number Publication Date
DE60305026D1 true DE60305026D1 (de) 2006-06-08
DE60305026T2 DE60305026T2 (de) 2006-10-12

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305026T Expired - Fee Related DE60305026T2 (de) 2002-04-26 2003-04-15 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Country Status (15)

Country Link
US (1) US6713490B2 (de)
EP (1) EP1499606B8 (de)
JP (1) JP2005524696A (de)
AR (1) AR039663A1 (de)
AT (1) ATE325117T1 (de)
AU (1) AU2003219398A1 (de)
BR (1) BR0309778A (de)
CA (1) CA2483636A1 (de)
DE (1) DE60305026T2 (de)
ES (1) ES2258716T3 (de)
MX (1) MXPA04010549A (de)
PA (1) PA8572601A1 (de)
TW (1) TW200406402A (de)
UY (1) UY27776A1 (de)
WO (1) WO2003091241A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1673367A1 (de) * 2003-10-08 2006-06-28 Pfizer, Inc. Kondensierte lactamverbindungen
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US8629184B2 (en) 2008-09-27 2014-01-14 TARAXOS, Inc. Topical formulations for treatment of neuropathy
WO2010113109A1 (en) * 2009-03-31 2010-10-07 Link Research & Grants Corporation Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013156614A1 (en) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH0699423B2 (ja) 1990-05-10 1994-12-07 フアイザー・インコーポレイテツド 神経保護性インドロン及び関連誘導体
PL173618B1 (pl) 1992-10-30 1998-04-30 Pfizer Związki 6-[2-(4-hydroksy-4-fenylopiperydyno)-1-hydroksypropylo]-3,4-dihydro-2(1H)-chinolonowe
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol

Also Published As

Publication number Publication date
US20030216430A1 (en) 2003-11-20
BR0309778A (pt) 2005-03-08
CA2483636A1 (en) 2003-11-06
JP2005524696A (ja) 2005-08-18
ATE325117T1 (de) 2006-06-15
US6713490B2 (en) 2004-03-30
MXPA04010549A (es) 2005-02-17
TW200406402A (en) 2004-05-01
DE60305026T2 (de) 2006-10-12
UY27776A1 (es) 2003-11-28
EP1499606B1 (de) 2006-05-03
PA8572601A1 (es) 2004-12-16
AR039663A1 (es) 2005-03-02
ES2258716T3 (es) 2006-09-01
EP1499606B8 (de) 2006-08-30
AU2003219398A1 (en) 2003-11-10
WO2003091241A1 (en) 2003-11-06
EP1499606A1 (de) 2005-01-26

Similar Documents

Publication Publication Date Title
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
AU2003259267A8 (en) Substituted aminopyrimidines as neurokinin antagonists
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
ATE494285T1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
ATE414074T1 (de) 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl- piperidine als cgrp-antagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
HK1093070A1 (en) Imidazole derivatives as glutamate receptor antagonists
DE60305026D1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
HK1058360A1 (en) 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists.
DE60333866D1 (de) 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
DE60133931D1 (de) Kondensierte purinderivate als a1-adenosinrezeptorantagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE403651T1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
ATE495168T1 (de) Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten
ATE504300T1 (de) Harnstoffderivate als il-8-rezeptorantagonisten
SG131946A1 (en) Ccr3 receptor antagonists
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER INC., NEW YORK, N.Y., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee